Aug 2026· International Immunopharmacology· Vol 187, pp.
117195
· 0 citations· 44 references
Medicine
TL;DR
Findings suggest that SLDS represents a promising therapeutic candidate for ASD by mitigating neuroinflammation and restoring hippocampal function, given that these observations are derived from preclinical models.
Abstract
Objective
Neuroinflammation plays a pivotal role in the pathogenesis of autism spectrum disorder (ASD) and represents a potential therapeutic target. Salidroside (SLDS), a bioactive compound isolated from Rhodiola rosea L., exhibits potent anti-inflammatory and neuroprotective effects in various neurological disorders; however, its therapeutic efficacy in ASD remains to be fully established. This study investigated whether SLDS ameliorates autism-like behaviors and hippocampal neuroinflammation in a valproic acid (VPA)-induced mouse model.
Methods
A total of 92 male C57BL/6 J mice were randomly assigned to four groups (n = 23 per group). Mice received a subcutaneous injection of VPA or saline on postnatal day 14 (P14), followed by intraperitoneal administration of SLDS or saline from postnatal day 28 (P28) for seven consecutive days. Behavioral assessments were conducted at 8 weeks of age. Hippocampal neuroinflammation, microglial polarization, and neurogenesis were analyzed by molecular, immunofluorescence, and histological techniques.
Results
VPA-exposed mice exhibited social interaction deficits, increased repetitive behaviors, elevated levels of pro-inflammatory cytokines, upregulated expression of inflammation-related proteins, microglial activation, and impaired hippocampal neurogenesis. SLDS treatment significantly attenuated these VPA-induced abnormalities.
Conclusion
Collectively, these findings suggest that SLDS represents a promising therapeutic candidate for ASD by mitigating neuroinflammation and restoring hippocampal function. Nevertheless, given that these observations are derived from preclinical models, further validation in translationally relevant experimental systems and clinical investigations is warranted before extrapolation to human therapeutic applications.
Investigation of Trigonelline's effects on autistic phenotype, gene expression of tight junction proteins associated with BBB integrity, neuroinflammation and histopathological changes in the hippocampus in valproic acid - induced autism in rats found it significantly attenuated autistic behaviors.
Zahra Forouzandeh Shahraki, A. Noori, Hossin Amini-Khoei et al.· World Journal of Biological...· 0 citations
Bacopa monnieri extract exerts protective effects against autism-like symptoms by enhancing antioxidant defenses and preserving neural integrity, suggesting its potential as a natural preventive strategy for ASD.
Zainab M. Almalki, A. Batawi, Asma Almuhammadi et al.· Molecules· 0 citations
Abstract Background Autism Spectrum Disorder (ASD) is a neurodevelopmental condition marked by social interaction deficits, communication challenges, and repetitive behaviors. The prevalence of ASD has increased significantly. Despite the growing recognition of ASD, effective pharmacological treatments for core symptom...
C. Zhu, Y. Chen, L. Zhang et al.· International Journal of Neu...· 0 citations
Preclinical evidence is provided that metformin can attenuate behavioral alterations associated with prenatal VPA exposure and modulate oxidative stress‐related markers, with patterns varying across sexes and brain regions.
Madna Costa Freitas, Renê Felipe de Freitas, Iara Késsila Milhome Vasconcelos et al.· Developmental Neurobiology· 0 citations
It is demonstrated that independently targeting oxidative stress or neuroinflammation achieves maximal behavioral and hippocampal rescue in an autism model, revealing a convergent therapeutic ceiling that challenges combinatorial polypharmacy and refines the understanding of how overlapping pathological pathways govern...
Results suggest that T10 improves learning and cognitive performance and reduces hippocampal inflammatory responses in 5xFAD mice, supporting its further investigation as a potential therapeutic intervention for AD.
Xue-Hai Ma, Wei-Ming Li, Yu-Mei Ma et al.· Molecular and cellular neuro...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.